Eli Lilly's Foundayo Pill Launch Shows Strong Initial Demand
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 30 2026
0mins
Source: CNBC
- Market Launch Performance: In the initial weeks post-launch, over 20,000 individuals have begun taking Eli Lilly's GLP-1 pill Foundayo, indicating strong market demand, with CEO David Ricks noting that more than 1,000 new users start daily, reflecting growing consumer interest in the new drug.
- FDA Approval and Market Competition: Foundayo received FDA approval earlier this month, becoming the second oral GLP-1 drug after Novo Nordisk's Wegovy, as Eli Lilly strives to maintain its dominance in the GLP-1 market, holding a 60.1% share of the U.S. obesity and diabetes drug market in Q1.
- Sales Growth Comparison: During the first quarter, sales of Lilly's Mounjaro and Zepbound surged by 125% and 80%, respectively, and while Foundayo's sales were not included in this quarter's results, its strong market launch suggests significant future growth potential.
- Brand Building Challenges: Ricks emphasized that as Foundayo is a new drug with limited awareness among doctors and patients, building the brand will take time; despite the current strong demand, he urges the market to exercise patience to allow the company to effectively execute its strategies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 966.990
Low
950.00
Averages
1192
High
1500
Current: 966.990
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Roche Secures CE Mark for Alzheimer's Blood Test
- CE Mark Approval: Swiss pharmaceutical company Roche announced that its second Elecsys blood test for Alzheimer's disease has received CE mark approval, allowing it to sell in the region and further expand its market share in the neuroscience sector.
- Collaborative Development: The test was developed in partnership with U.S. company Eli Lilly, highlighting the ongoing collaboration between the two firms in the early diagnosis of Alzheimer's disease, which is expected to enhance market acceptance and clinical application of related products.
- Market Potential: With the global increase in Alzheimer's disease patients, the new testing tool will aid in early identification and intervention, thereby improving patient quality of life and alleviating the burden on healthcare systems, presenting significant social and economic implications.
- Strategic Importance: Securing CE mark not only strengthens Roche's competitive position in the Alzheimer's field but also lays the groundwork for future innovative product launches in the European market, reflecting the company's long-term commitment to the neuroscience domain.
See More
Eli Lilly Halts Obesity Awareness Campaign in India
- Regulatory Warning: The Drugs Controller General of India warned Eli Lilly that its obesity awareness campaign could violate prescription drug advertising regulations, prompting the company to pause its 'We Know Now' initiative to avoid potential legal risks, highlighting the strict and uncertain regulatory environment.
- Market Context: Lilly launched its GLP-1 treatment Mounjaro in India in March 2025 to address the rising obesity issue, with a government survey from 2019 to 2021 indicating that approximately 24% of women aged 15-49 and nearly 23% of men aged 15-54 were overweight or obese, showcasing significant market demand.
- Campaign Impact: Although Lilly's campaign aimed to enhance public understanding of obesity, the regulator's intervention forced the cessation of this scientifically-backed public health initiative, potentially harming the interests of patients and the healthcare community, reflecting the company's conflict between regulatory compliance and public health promotion.
- Industry Uncertainty: Lilly noted in its letter that the guidance from the regulator created 'significant regulatory uncertainty' and questioned whether even non-branded, physician-led initiatives would be restricted, illustrating the ambiguity and challenges faced by the industry in regulatory enforcement.
See More
Novo Nordisk's New Data Boosts Weight Loss Drug Market
- Significant New Dose Effects: Novo Nordisk's new data presented at the European Congress on Obesity indicates that patients using the 7.2 mg high-dose Wegovy lost an average of 27.7% of their weight over 72 weeks, showcasing the drug's potential in weight loss treatment, which may attract more prescribers and patients.
- Intensified Market Competition: The weight loss efficacy of high-dose Wegovy is comparable to Eli Lilly's Zepbound, both exceeding 20%, positioning Novo to potentially regain market share, especially as Zepbound has become the preferred obesity drug.
- Early Responders Analysis: In the trial, about one in four high-dose patients exhibited early treatment responses, losing over 15% of their weight, compared to one in five for the 2.4 mg dose, highlighting the potential advantages of the higher dosage.
- Market Dynamics Uncertainty: Despite the encouraging new data, analysts caution that it remains unclear whether high-dose Wegovy will significantly alter the market share dynamics between Novo and Lilly, as Zepbound's entrenched position in the market persists.
See More
Hims & Hers Health Misses Q1 Revenue Estimates, Shares Drop 15%
- Earnings Decline: Hims & Hers Health reported a loss of $0.40 per share for Q1, significantly missing analysts' expectations of a $0.04 profit, highlighting the financial strain during the company's transition period.
- Strategic Shift: The company pivoted towards branded GLP-1 weight-loss drugs during the quarter, which is expected to lead to profitability by 2027, but has pressured margins and domestic sales in the short term.
- Revenue Recognition Changes: The shift to shorter shipping schedules altered the timing of revenue recognition for some weight-loss products, impacting overall U.S. revenue performance and reflecting the challenges the company faces in adapting to the new market environment.
- Regulatory Risks: The FDA's restrictions on compounded versions of GLP-1 drugs and referral to the Department of Justice pose potential legal risks, with this news previously causing the company's shares to drop over 10% earlier this year.
See More
Novo Nordisk's Wegovy Data Shows Significant Weight Loss Improvements
- Significant Weight Loss Results: Novo Nordisk's study reveals that patients taking the 7.2 mg Wegovy lost an average of 27.7% of their body weight over 72 weeks, demonstrating faster weight loss compared to the standard 2.4 mg dose, thereby enhancing the company's competitive edge in the obesity drug market.
- Fat Reduction with Muscle Preservation: The data indicates that 84% of the weight loss was due to reductions in body fat while muscle strength and health were largely preserved, suggesting that Wegovy effectively protects muscle health during weight loss, increasing the drug's appeal.
- Intensifying Market Competition: Following the release of new data, Novo's shares rose 3% in premarket trading, reflecting increased market confidence in its obesity drug, particularly as it seeks to narrow the gap with Eli Lilly in the competitive landscape.
- New Drug Rollout and Regulatory Progress: Novo has launched the higher-dose Wegovy in the U.S. and is seeking approval for a single-dose 7.2 mg pen in Europe and the U.K., which is expected to further expand its market share and meet the growing demand for obesity treatments.
See More
HIMS' AI Healthcare Platform Potential Underestimated by Investors
- Underestimated Potential: Raul Shah of DocShah Financial argues that investors are misjudging HIMS' AI-driven healthcare ambitions, suggesting that partnerships with Novo and Lilly could be the first of many pharma collaborations that reshape the healthcare landscape.
- Significant Shipments: HIMS fulfilled over 125,000 Wegovy shipments within six weeks of launching Novo Nordisk's GLP-1 products, demonstrating its rapid market responsiveness and ability to meet customer demand effectively.
- Enhanced Financial Flexibility: HIMS raised $1 billion in convertible debt last year, providing it with greater financial flexibility to acquire existing healthcare platforms internationally, allowing for swift market expansion in a competitive landscape.
- Optimistic Future Outlook: Despite disappointing Q1 results, HIMS raised its full-year 2026 revenue guidance to $2.8 billion to $3 billion, reflecting the company's confidence in its growth strategy and future market positioning.
See More
Roche Secures CE Mark for Alzheimer's Blood Test
- CE Mark Approval: Swiss pharmaceutical company Roche announced that its second Elecsys blood test for Alzheimer's disease has received CE mark approval, allowing it to sell in the region and further expand its market share in the neuroscience sector.
- Collaborative Development: The test was developed in partnership with U.S. company Eli Lilly, highlighting the ongoing collaboration between the two firms in the early diagnosis of Alzheimer's disease, which is expected to enhance market acceptance and clinical application of related products.
- Market Potential: With the global increase in Alzheimer's disease patients, the new testing tool will aid in early identification and intervention, thereby improving patient quality of life and alleviating the burden on healthcare systems, presenting significant social and economic implications.
- Strategic Importance: Securing CE mark not only strengthens Roche's competitive position in the Alzheimer's field but also lays the groundwork for future innovative product launches in the European market, reflecting the company's long-term commitment to the neuroscience domain.
See More
Eli Lilly Halts Obesity Awareness Campaign in India
- Regulatory Warning: The Drugs Controller General of India warned Eli Lilly that its obesity awareness campaign could violate prescription drug advertising regulations, prompting the company to pause its 'We Know Now' initiative to avoid potential legal risks, highlighting the strict and uncertain regulatory environment.
- Market Context: Lilly launched its GLP-1 treatment Mounjaro in India in March 2025 to address the rising obesity issue, with a government survey from 2019 to 2021 indicating that approximately 24% of women aged 15-49 and nearly 23% of men aged 15-54 were overweight or obese, showcasing significant market demand.
- Campaign Impact: Although Lilly's campaign aimed to enhance public understanding of obesity, the regulator's intervention forced the cessation of this scientifically-backed public health initiative, potentially harming the interests of patients and the healthcare community, reflecting the company's conflict between regulatory compliance and public health promotion.
- Industry Uncertainty: Lilly noted in its letter that the guidance from the regulator created 'significant regulatory uncertainty' and questioned whether even non-branded, physician-led initiatives would be restricted, illustrating the ambiguity and challenges faced by the industry in regulatory enforcement.
See More
Novo Nordisk's New Data Boosts Weight Loss Drug Market
- Significant New Dose Effects: Novo Nordisk's new data presented at the European Congress on Obesity indicates that patients using the 7.2 mg high-dose Wegovy lost an average of 27.7% of their weight over 72 weeks, showcasing the drug's potential in weight loss treatment, which may attract more prescribers and patients.
- Intensified Market Competition: The weight loss efficacy of high-dose Wegovy is comparable to Eli Lilly's Zepbound, both exceeding 20%, positioning Novo to potentially regain market share, especially as Zepbound has become the preferred obesity drug.
- Early Responders Analysis: In the trial, about one in four high-dose patients exhibited early treatment responses, losing over 15% of their weight, compared to one in five for the 2.4 mg dose, highlighting the potential advantages of the higher dosage.
- Market Dynamics Uncertainty: Despite the encouraging new data, analysts caution that it remains unclear whether high-dose Wegovy will significantly alter the market share dynamics between Novo and Lilly, as Zepbound's entrenched position in the market persists.
See More
Hims & Hers Health Misses Q1 Revenue Estimates, Shares Drop 15%
- Earnings Decline: Hims & Hers Health reported a loss of $0.40 per share for Q1, significantly missing analysts' expectations of a $0.04 profit, highlighting the financial strain during the company's transition period.
- Strategic Shift: The company pivoted towards branded GLP-1 weight-loss drugs during the quarter, which is expected to lead to profitability by 2027, but has pressured margins and domestic sales in the short term.
- Revenue Recognition Changes: The shift to shorter shipping schedules altered the timing of revenue recognition for some weight-loss products, impacting overall U.S. revenue performance and reflecting the challenges the company faces in adapting to the new market environment.
- Regulatory Risks: The FDA's restrictions on compounded versions of GLP-1 drugs and referral to the Department of Justice pose potential legal risks, with this news previously causing the company's shares to drop over 10% earlier this year.
See More
Novo Nordisk's Wegovy Data Shows Significant Weight Loss Improvements
- Significant Weight Loss Results: Novo Nordisk's study reveals that patients taking the 7.2 mg Wegovy lost an average of 27.7% of their body weight over 72 weeks, demonstrating faster weight loss compared to the standard 2.4 mg dose, thereby enhancing the company's competitive edge in the obesity drug market.
- Fat Reduction with Muscle Preservation: The data indicates that 84% of the weight loss was due to reductions in body fat while muscle strength and health were largely preserved, suggesting that Wegovy effectively protects muscle health during weight loss, increasing the drug's appeal.
- Intensifying Market Competition: Following the release of new data, Novo's shares rose 3% in premarket trading, reflecting increased market confidence in its obesity drug, particularly as it seeks to narrow the gap with Eli Lilly in the competitive landscape.
- New Drug Rollout and Regulatory Progress: Novo has launched the higher-dose Wegovy in the U.S. and is seeking approval for a single-dose 7.2 mg pen in Europe and the U.K., which is expected to further expand its market share and meet the growing demand for obesity treatments.
See More
HIMS' AI Healthcare Platform Potential Underestimated by Investors
- Underestimated Potential: Raul Shah of DocShah Financial argues that investors are misjudging HIMS' AI-driven healthcare ambitions, suggesting that partnerships with Novo and Lilly could be the first of many pharma collaborations that reshape the healthcare landscape.
- Significant Shipments: HIMS fulfilled over 125,000 Wegovy shipments within six weeks of launching Novo Nordisk's GLP-1 products, demonstrating its rapid market responsiveness and ability to meet customer demand effectively.
- Enhanced Financial Flexibility: HIMS raised $1 billion in convertible debt last year, providing it with greater financial flexibility to acquire existing healthcare platforms internationally, allowing for swift market expansion in a competitive landscape.
- Optimistic Future Outlook: Despite disappointing Q1 results, HIMS raised its full-year 2026 revenue guidance to $2.8 billion to $3 billion, reflecting the company's confidence in its growth strategy and future market positioning.
See More
